The Association between Monocyte Surface CD163 and Insulin Resistance in Patients with Type 2 Diabetes

Table 1

Clinical characteristics of 166 patients with type 2 diabetes.

(male/female)	166 (96/70)
Age (years)	61.0 ± 13.0
Duration (years)	13.6 ± 11.4
BMI (kg/m^2)	25.7 ± 5.48
SBP (mmHg)	128 ± 17.4
DBP (mmHg)	73.8 ± 9.3
HbA1c (%)	8.31 ± 1.66
HOMA-R	2.12 (1.22–3.05)
TC (mg/dL)	174 ± 51.2
TG (mg/dL)	110 (81–136)
LDL-C (mg/dL)	104 ± 36.6
HDL-C (mg/dL)	41.9 ± 11.9
FFA (mEq/L)	0.52 ± 0.23
Cre (mg/dL)	0.80 ± 0.23
ARB (yes/no)	67/99
Statin (yes/no)	79/87
hsTNFα (pg/mL)	1.57 (1.16–1.92)
hsCRP (ng/mL)	604.3 (291.1–1681.5)
Soluble CD163 (ng/mL)	582.9 (472.4–720.0)
Monocyte CD163 (MFI)	6061 (4486–7876)

Data are expressed as (%), mean ± SD, or median (interquartile range) as appropriate. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin A1c; HOMA-R: homeostasis model assessment of insulin resistance; TC: total cholesterol; TG: triglycerides; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; FFA: free fatty acid; Cre: creatinine; ARB: angiotensin-II receptor antagonists; hsTNFα: high sensitive tumor necrosis factor alpha; hsCRP: high sensitive C reactive protein.